**bs-1659R** **[ Primary Antibody ]**

# phospho-STAT5a (Tyr694) Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

## DATASHEET

**Host:** Rabbit **Isotype:** IgG

**Clonality:** Polyclonal

**GeneID:** 6776 **SWISS:** P42229

**Target:** phospho-STAT5a (Tyr694)

**Immunogen:** KLH conjugated Synthesised phosphopeptide derived from human STAT5a around the phosphorylation site of Tyr694: DG(p-Y)VK.

**Purification:** affinity purified by Protein A

**Concentration:** 1mg/ml

**Storage:** 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

**Background:** The protein encoded by this gene is a member of the STAT family of transcription factors. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein is activated by, and mediates the responses of many cell ligands, such as IL2, IL3, IL7 GM-CSF, erythropoietin, thrombopoietin, and different growth hormones. Activation of this protein in myeloma and lymphoma associated with a TEL/JAK2 gene fusion is independent of cell stimulus and has been shown to be essential for the tumorigenesis. The mouse counterpart of this gene is found to induce the expression of BCL2L1/BCL-X(L), which suggests the antiapoptotic function of this gene in cells. [provided by RefSeq, Jul 2008]

**Applications:** **WB** (1:500-2000)
**ELISA** (1:5000-10000)

**Reactivity:** Human (predicted: Mouse, Rat, Rabbit, Pig, Sheep, Cow, Chicken, Dog)

**Predicted MW.:** 91 kDa

**Subcellular Location:** Cytoplasm ,Nucleus

## SELECTED CITATIONS


- **[IF=5]** Ling Zuo. et al. Therapeutic potential of icariin in rats with letrozole and high-fat diet-induced polycystic ovary syndrome. EUR J PHARMACOL. 2023 Jun;:175825 WB ;Rat. 37269973
- **[IF=4.7]** Shuo Wang. et al. Structure Optimization, Synthesis and Bioactivity Evaluation of Novel BCR-ABL Tyrosine Kinase Inhibitor Targeting T315I Mutation. CHEM-BIOL INTERACT. 2024 Sep;:111248 WB ;Human. 39332790